Imidazoquinoline compound, preparation method therefor, and use and composition thereof
By selectively releasing TLR7/8 agonists within tumors through imidazoquinoline compounds, tumor immune cells are activated, thus solving the problem of systemic immunotoxicity of small molecule TLR7/8 agonists and achieving the effects of tumor antigen-specific immune activation and reduced systemic toxicity.
Patent Information
- Application Number
- PCT/CN2024/090446
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-04-28
- Publication Date
- 2024-11-21
AI Technical Summary
Existing small molecule TLR7/8 agonists lack specific targeting, resulting in simultaneous action on immune cells both inside and outside the tumor after administration, causing systemic immunotoxicity problems.
An imidazoquinoline compound is provided that activates intratumoral immune cells by selectively releasing TLR7/8 receptor-activating molecules within the tumor, thereby reducing the agonistic activity of TLR7/8 receptors outside the tumor and decreasing systemic immunotoxicity.
It achieves antigen-specific T-cell immune activation within the tumor, while reducing the activation of extratumor immune cells, reducing systemic immunotoxicity, improving anti-tumor efficacy, and reducing systemic toxic side effects.
Smart Images

Figure CN2024090446_21112024_PF_FP_ABST
Abstract
Description
Imidazoloquinoline compound and its preparation method, application and composition
[0001] This application claims priority to the Chinese patent application filed with the China Patent Office on May 18, 2023, with application number 202310566830X, entitled “Imidazoloquinoline compounds, preparation methods, applications and compositions thereof”, the entire contents of which are incorporated herein by reference. Technical Field
[0002] The present application belongs to the field of medical technology, and specifically relates to an imidazoquinoline compound and its preparation method, application and composition. Background Art
[0003] Toll-like receptors (TLRs) are widely expressed in the immune cell spectrum and participate in nonspecific immunity and mediate specific immunity. TLRs are the innate immune system that monitors and recognizes various disease-associated molecular patterns (PAMPs) and are the body's first barrier to infectious diseases. Currently, 13 TLRs (TLR1-TLR13) have been identified in mammals, including TLR1-TLR11 in humans, TLR1-TLR9 and TLR11-TLR13 in mice. Activation of TLRs can induce MyD88- or TRIF-dependent signaling pathways, thereby activating NF-κB, inducing cytokine and chemokine secretion, activating innate immune responses, and mediating acquired immune responses. Therefore, TLR agonists can be used as immune adjuvants for anti-tumor and infectious disease treatment.
[0004] TLR7 / 8 agonists are an important component of TLR agonists. TLR7 / 8 agonists include the imidazoquinoline family IMQ, such as imiquimod (R837) and resiquimod (R848). When these TLR7 / 8 agonists such as R848 are used as adjuvants, they are small molecule compounds that do not have specific targeting and have a short half-life. Intravenous injection can lead to systemic immune system hyperactivity, which in turn leads to cytokine release syndrome (CRS), which is difficult to tolerate in vivo. Therefore, TLR7 / 8 agonists are widely considered to be effective adjuvants for local anti-tumor therapy.
[0005] Although TLR7 / 8 agonists are effective adjuvants for local anti-tumor therapy, their severe toxic side effects are a major issue facing current clinical applications. The toxic side effects of TLR7 / 8 agonists are due to the presence of a large number of non-tumor cells, including various immune cells, fibroblasts, and stromal cells, in the cellular composition of the solid tumor microenvironment, in addition to a large number of tumor cells. These cells include various immune cells, fibroblasts, and stromal cells. Unlike conventional cytotoxic drugs such as antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs), which act on tumor cells after being released into the tumor, TLR7 / 8 agonists target immune cells within the tumor, including both pre-existing immune cells and immune cells induced to infiltrate by TLR7 / 8 agonists. When TLR7 / 8 agonists are delivered into the tumor, they are phagocytosed by immune cells, particularly antigen-presenting cells (APCs) such as dendritic cells (DCs). This activates TLR7 and TLR8 receptors on cytoplasmic endosomes, which, through the MYD88-mediated NF-KB signaling pathway, activates the expression of inflammatory cytokines and induces the secretion of cytokines IFN-α, IFN-γ, TNF-α, IL-1β, IL-12p40, and IP-10. Activated APCs then present antigens to T cells, mediating antigen-specific T cell anti-tumor immunity. Therefore, small molecule TLR7 / 8 agonists, after activating TLR7 / 8 receptors, can promote the release of tumor antigens and mediate tumor antigen-specific T cell immunity, activating T cells that circulate throughout the body to kill distant metastatic tumors, achieving in situ immune activation and inducing systemic anti-tumor immune effects. However, since small molecule TLR7 / 8 agonists do not have specific targeting, even if such small molecule TLR7 / 8 agonists are administered by intratumoral injection, it is still difficult to overcome the problem of systemic immunotoxicity caused by rapid absorption. Technical issues
[0006] The purpose of this application is to provide an imidazoquinoline compound and its preparation method, application and composition, so as to solve the technical problem in the prior art that small molecule TLR7 / 8 agonists do not have specific targeting and, after administration, act on immune cells both inside and outside the tumor, causing systemic immunotoxicity. Technical Solutions
[0007] In order to achieve the above application objectives, one aspect of the present application provides an imidazoquinoline compound. The imidazoquinoline compound of the present application is a compound represented by Formula I, or a pharmaceutically acceptable salt thereof:
[0008] X includes any one of n-propyl, n-butyl, n-butylamine, n-pentyl, and 2-methoxyethyl;
[0009] R1 includes C1-C 36 Alkyl, C1-C 36 Any of the alkoxy groups;
[0010] R2 includes any one of hydrogen, substituted or unsubstituted aryl, condensed ring aryl, heteropolycyclic group, and -S-R3, wherein R3 includes any one of substituted or unsubstituted aryl, condensed ring aryl, and heteropolycyclic group.
[0011] Furthermore, X is n-butyl.
[0012] Furthermore, the structure of the imidazoquinoline compound is shown in formula (1):
[0013] Furthermore, the structure of the imidazoquinoline compound is shown in formula (2):
[0014] Furthermore, R3 is represented by Formula II:
[0015] Wherein, X1 includes any one of n-propyl, n-butyl, n-butylamine, n-pentyl, and 2-methoxyethyl, and R4 includes C1-C 36 Alkyl, C1-C 36 Any of the alkoxy groups.
[0016] Furthermore, the structure of the imidazoquinoline compound is shown in formula (3):
[0017] Furthermore, the structure of the imidazoquinoline compound is shown in formula (4):
[0018] Another aspect of the present application provides a method for preparing an imidazoquinoline compound. The method for preparing an imidazoquinoline compound of the present application comprises the following steps:
[0019] Compound A and Compound B are provided:
[0020] Compound A and compound B are subjected to a first condensation reaction to obtain an imidazoquinoline compound represented by formula I;
[0021] Wherein, Y includes -COOH, Any of;
[0022] Z includes hydrogen, substituted or unsubstituted aryl, fused ring aryl, heteropolycyclic group, Any one of wherein R4 comprises C1-C36 Alkyl, C1-C 36 Any of the alkoxy groups, X2 includes hydrogen, Any of .
[0023] Furthermore, the reaction solvent of the first condensation reaction includes at least one of tetrahydrofuran, triethylamine, diisopropylethylamine, 4-dimethylaminopyridine, N,N-dimethylformamide, and dichloromethane.
[0024] Furthermore, the molar ratio of compound A to compound B is 1:1 to 1:10.
[0025] Furthermore, the concentration of compound A in the reaction solution system of the first condensation reaction is 5 to 20 mg / ml.
[0026] Furthermore, the reaction solution system of the first condensation reaction contains a condensation reagent, and the molar ratio of compound A to the condensation reagent is 1:3 to 1:15.
[0027] Furthermore, the condensation reagent includes at least one of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N-diisopropylethylamine, N,N'-diisopropylcarbodiimide, 1-hydroxybenzotriazole, 1-propylphosphoric anhydride, dicyclohexylcarbodiimide, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.
[0028] Furthermore, the reaction temperature of the first condensation reaction is 20-25°C.
[0029] Furthermore, the reaction time of the first condensation reaction is 2 to 18 hours.
[0030] Furthermore, when Z is hydrogen, after the first condensation reaction, the preparation method further includes conducting a second condensation reaction between the product molecules of the first condensation reaction, and the second condensation reaction is a thiol dehydrogenation oxidation reaction, wherein the thiol group is the thiol group contained in the imidazoquinoline compound shown in Formula I.
[0031] In another aspect of the present application, there is provided the use of an imidazoquinoline compound in the preparation of an anti-tumor drug and / or an antiviral drug.
[0032] Furthermore, the solid tumor includes at least one of cutaneous T-cell lymphoma, melanoma, breast cancer, colorectal cancer, lung cancer, pancreatic cancer, prostate cancer, ovarian cancer, bone cancer, and brain tumor.
[0033] Furthermore, the administration of the anti-tumor drug may include but is not limited to at least one of intratumoral injection, peritumoral injection, subcutaneous injection, intraperitoneal injection, and intravenous injection.
[0034] Furthermore, the dosage of the anti-tumor drug is 0.0005 to 0.04 mg / kg.
[0035] Further, the virus includes hepatitis B virus.
[0036] Furthermore, the administration of the antiviral drug includes but is not limited to at least one of subcutaneous injection, intraperitoneal injection, and intravenous injection.
[0037] In another aspect of the present application, a composition is provided, which comprises an imidazoquinoline compound.
[0038] Furthermore, the composition includes pharmaceutically acceptable excipients.
[0039] Compared with the existing technology, this application has the following technical effects:
[0040] The imidazoquinoline compound of the present application is a TLR7 / 8 agonist or a derivative thereof. After administration, the imidazoquinoline compound selectively decomposes and releases molecules with TLR7 / 8 receptor agonist activity in the tumor, while no or almost no molecules with TLR7 / 8 receptor agonist activity are released in the environment outside the tumor, such as plasma. Therefore, the imidazoquinoline compound of the present application selectively releases TLR7 / 8 agonists in the tumor, mainly acting on immune cells in the tumor, activating TLR7 and TLR8 receptors on cytoplasmic endosomes.
[0041] Furthermore, the imidazoquinoline compound of the present application selectively releases molecules with TLR7 / 8 receptor stimulating activity in tumors, so that the molecules selectively act on immune cells in tumors, activate TLR7 and TLR8 receptors on cytoplasmic endosomes, and activate the expression of inflammatory cytokines through the MYD88-mediated NF-KB signaling pathway, inducing the secretion of inflammatory cytokines such as TNF-α, and mediating antigen-specific T cell anti-tumor immunity. On this basis, the imidazoquinoline compound effectively reduces the content of TLR7 / 8 agonists outside the tumor, reduces or avoids the effect on immune cells outside the tumor, and minimizes the non-specific immunotoxicity caused by cytokine storms such as TNF-α while achieving anti-tumor effects.
[0042] The preparation method of the present application is to carry out a condensation reaction between compound A and compound B, so that the amino group on the para position of the benzene ring of compound A and compound B undergoes a condensation reaction, and the amino group on the para position of the benzene ring of compound A is acylated to form an amide bond to prepare an imidazoquinoline compound. The preparation method has a high yield and few by-products. The imidazoquinoline compound can be a prodrug that can selectively release active molecules with TLR7 / 8 receptor stimulating properties in the tumor in vivo, thereby inducing systemic anti-tumor immunity after in situ activation of the tumor, while reducing the effect on immune cells outside the tumor and reducing systemic immunotoxicity.
[0043] The imidazoquinoline compound of the present application selectively releases TLR7 / 8 agonists in tumors, so that the TLR7 / 8 agonist molecules mainly act on immune cells in the tumor, mediate antigen-specific T cell anti-tumor immunity, achieve in situ immune activation, and effectively reduce the agonistic activity of TLR7 / 8 receptors on immune cells outside the tumor, thereby reducing systemic immunotoxicity, so that the imidazoquinoline compound is applied to anti-tumor drugs, and has the beneficial effect of low systemic immunotoxicity while having anti-tumor activity. In addition, the imidazoquinoline compound of the present application also has good antiviral effects and can be used to prepare antiviral drugs.
[0044] Since the composition of the present application contains an imidazoquinoline compound that acts on immune cells in the tumor in a targeted manner, the composition reduces or avoids the effect on immune cells outside the tumor on the basis of having anti-tumor activity, reduces the expression of inflammatory cytokines in the plasma, and effectively reduces systemic immunotoxicity. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the following is a brief introduction to the drawings required for use in the specific implementation methods or the description of the prior art. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without any creative work.
[0046] FIG1 is a process flow chart of a method for preparing an imidazoquinoline compound according to an embodiment of the present application;
[0047] FIG2 is a process flow chart of the method for preparing an imidazoquinoline compound provided in an embodiment of the present application, including the second condensation reaction step;
[0048] Figure 3 is the H-NMR spectrum of 78A1-SH;
[0049] Figure 4 is a H-NMR spectrum of 78A1-S-Trityl;
[0050] FIG5 is a H-NMR spectrum of 78A1-SS-78A1;
[0051] FIG6 is a mass spectrum of 78A1-SS-78A1;
[0052] FIG7 is a schematic diagram showing the detection results of the induction expression activity of TNF-α in lymphocytes by R848, 78A1, 78A1-SH, 78A1-S-Trityl and 78A1-SS-78A1 in Example B1;
[0053] FIG8 is a schematic diagram showing the results of serum TNF-α detection after subcutaneous injection of 78A1 and 78A1-SS-78A1 in Example B2, wherein A in FIG8 is a line graph and B in FIG8 is a bar graph;
[0054] FIG9 is a schematic diagram showing the results of serum TNF-α detection 1 hour after subcutaneous injection of R848, 78A1, 78A1-SH, 78A1-S-Trityl, and 78A1-SS-78A1 in Example B3;
[0055] FIG10 is a schematic diagram showing the results of serum and tumor TNF-α levels at different time points following intratumoral injection of 78A1 and 78A1-SS-78A1 in Example B4, wherein A in FIG10 represents the serum TNF-α level, and B in FIG10 represents the tumor TNF-α level;
[0056] FIG11 is a schematic diagram showing the results of TNF-α level detection in serum and tumor 1 hour after intratumoral injection of R848, 78A1, 78A1-S-Trityl, and 78A1-SS-78A1 in Example B5, wherein A in FIG11 is the TNF-α level in serum, and B in FIG11 is the TNF-α level in tumor;
[0057] FIG12 is a schematic diagram showing changes in mouse body weight under different dosing conditions in Example B6;
[0058] FIG13 is a schematic diagram of the tumor growth curves of Example B6 obtained by rapid intratumoral injection of PBS, 78A1 10 μg, 78A1-S-Trityl 10 μg, 78A1-SH 10 μg, 78A1-SS-78A1 10 μg, 78A1-SS-78A1 20 μg, and microinjection pump injection of 78A1-SS-78A1 20 μg;
[0059] Figure 14 is a schematic diagram summarizing the tumor growth curves of Example B6;
[0060] FIG15 is a schematic diagram of the tumor weight detection results of Example B6;
[0061] Figure 16 is a schematic diagram of tumor size at the endpoint of the experiment in Example B6;
[0062] Figure 17 is a schematic diagram of the cytokine detection results of PBMC cells in Example B7, wherein Figure 17 A is a schematic diagram of the TNF-α secretion level results, Figure 17 B is a schematic diagram of the IFN-α secretion level results, Figure 17 C is a schematic diagram of the IL-6 secretion level results, and Figure 17 D is a schematic diagram of the IL-12p70 secretion level results;
[0063] FIG18 is a schematic diagram of the blood drug concentration of Example B878A1-SS-78A1 after subcutaneous and intravenous injection;
[0064] FIG19 is a schematic diagram of tumor changes after intratumoral and peritumoral injections in Example B9, wherein FIG19A is a schematic diagram of tumor volume changes, and FIG19B is a schematic diagram of the tumor after dissection;
[0065] FIG20 is a graph showing the survival rates of mice injected intraperitoneally with PBS and mice injected intraperitoneally with 78A1-SS-78A1 according to Example B10;
[0066] FIG21 is a schematic diagram of the abdominal cavity anatomy of mice intraperitoneally injected with PBS and mice intraperitoneally injected with 78A1-SS-78A1 in Example B10;
[0067] FIG22 is a schematic diagram showing the changes in tumor volume in mice at different dosages of Example B11;
[0068] FIG23 is a schematic diagram showing the results of weight changes of mice under different dosing conditions in Example B12. Modes for Carrying Out the Invention
[0069] In order to make the technical problems, technical solutions and beneficial effects to be solved by this application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain this application and are not intended to limit this application.
[0070] In a first aspect, the present invention provides an imidazoquinoline compound (IMQ), which is a compound of formula I or a pharmaceutically acceptable salt thereof:
[0071] X includes any one of n-propyl, n-butyl, n-butylamine, n-pentyl, and 2-methoxyethyl;
[0072] R1 includes C1-C 36 Alkyl, C1-C 36 Any of the alkoxy groups;
[0073] R2 includes any one of hydrogen, substituted or unsubstituted aryl, condensed ring aryl, heteropolycyclic group, and -S-R3, wherein R3 includes any one of substituted or unsubstituted aryl, condensed ring aryl, and heteropolycyclic group.
[0074] After being engulfed by immune cells, small molecule TLR7 / 8 agonists can activate TLR7 and TLR8 receptors on cytoplasmic endosomes, mediating antigen-specific T cell anti-tumor immunity. Since small molecule TLR7 / 8 agonists are not targeted, they are distributed not only within the tumor but also outside the tumor after administration. TLR7 / 8 agonist molecules distributed within the tumor can promote the release of tumor antigens and mediate tumor antigen-specific T cell immunity, but TLR7 / 8 agonist molecules distributed outside the tumor act on immune cells outside the tumor, causing the body's immune response outside the tumor, leading to an increase in cytokines such as TNF-α, and even leading to a cytokine storm and systemic immune system hyperactivity, causing systemic immunotoxicity.
[0075] The imidazoquinoline compound of the present application embodiment is a compound obtained after aminoacylation on the para position of the benzene ring of the TLR7 / 8 agonist, containing an amide bond, and also including at least one of a sulfhydryl group, a thioether bond, and a disulfide bond. After administration, the imidazoquinoline compound can selectively release molecules with exciting TLR7 / 8 receptor activity in the tumor, activate the TLR7 and TLR8 receptors of immune cells in the tumor, activate the expression of inflammatory cytokines, promote the release of tumor antigens and mediate tumor antigen-specific T cell immunity, achieve in situ immune activation, and induce anti-tumor immune effects. At the same time, the imidazoquinoline compound of the present application embodiment can reduce or avoid the release of molecules with exciting TLR7 / 8 receptor activity outside the tumor, reduce or avoid the activation of immune cells outside the tumor, and greatly reduce the possibility of systemic immune system hyperactivity and cytokine release syndrome (CRS). The imidazoquinoline compound in the embodiment of the present application selectively releases molecules with TLR7 / 8 receptor stimulating activity in tumors, so that the imidazoquinoline compound has anti-tumor activity while greatly reducing toxic side effects such as systemic immunotoxicity to the body.
[0076] In some embodiments, X is 2-methoxyethyl (-CH2OCH2CH3).
[0077] In some embodiments, X is n-butyl (-CH2CH2CH2CH3). In this case, the structural formula of the imidazoquinoline compound of the present embodiment is as shown in Formula I1.
[0078] When X is n-butyl, the imidazoquinoline compound represented by the above formula I1 can be obtained by reacting the following molecule 78A1 as a raw material.
[0079] 78A1, with the CAS number 1258457-59-8, is a small molecule TLR7 / 8 agonist with excellent anti-tumor activity. However, after administration, 78A1 is distributed not only within the tumor but also outside the tumor. This not only activates the immune response within the tumor, increasing the production of cytokines such as TNF-α within the tumor and mediating antigen-specific T cell anti-tumor immunity, but also because the 78A1 receptor is also distributed outside the tumor, such as in plasma, 78A1 also activates the immune response outside the tumor, leading to increased levels of cytokines outside the tumor and, in turn, causing immunotoxicity.
[0080] After administration, the compound represented by Formula I1 can selectively release molecules with TLR7 and TLR8 receptor stimulating activity inside the tumor, specifically increase the secretion of cytokines and chemokines in the tumor, mediate antigen-specific T cell anti-tumor immunity, and have a good anti-tumor effect. At the same time, it reduces or avoids the activation of TLR7 and TLR8 receptors of immune cells outside the tumor, reduces or avoids the increased secretion of cytokines and chemokines such as TNF-α outside the tumor of the body, and reduces the non-specific immunotoxicity caused by cytokine storms such as TNF-α.
[0081] In some embodiments, R1 can be -(CH2CH2O) n -, wherein n=1-36, further, n=1-20, further, n=1-10, further, n=1-5, and specifically, n can be typical but non-limiting values such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 26, 30, 35.
[0082] In a specific example, R1 may include any one of -CH2CH2O-, -CH2OCH2-, -CH2OCH2CH2-, -CH2CH2OCH2-, and -CH2CH2OCH2CH2-.
[0083] In some embodiments, R1 can be -(CH2) m -, wherein m = 1-36, further, m = 1-20, further, m = 1-10, further, m = 1-5, and specifically, m can be typical but non-limiting values such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 26, 30, 35.
[0084] In a specific example, R1 may include any one of -CH2CH2-, -CH2-, -(H2CH2)2-, -(CH2CH2)3-, and -(CH2CH2)4-.
[0085] In some embodiments, R2 may be hydrogen. In this case, the structural formula of the imidazoquinoline compound of the present invention is as shown in Formula I2.
[0086] The molecule shown in Formula I2 is a thiol derivative of a TLR7 / 8 agonist. It contains a thiol group -SH, which makes it susceptible to oxidation. However, after oxidation, it can restore the structure of the -SH group in a reducing environment, allowing it to have a certain activity in stimulating TLR7 / 8 receptors. At the same time, since the concentration of glutathione (glutathione, r-glutamyl cysteingl+glycine, GSH) in the blood is low and the GSH content in the tumor is high, the molecule shown in Formula I2 in the tumor tends to exist in a reduced -SH form. Therefore, even after administration by intraperitoneal injection, while the content of pro-inflammatory cytokines in the tumor increases, the level of pro-inflammatory cytokines such as TNF-α in the blood is not too high.
[0087] In addition, when R1 is C1-C 36 Alkyl or C1-C 36 Alkoxy, for example R1 is -(CH2CH2O) n -or-(CH2) m -, the length of the carbon chain of R1 is different, and the activity of the molecule shown in I2 is different. When the length of the carbon chain is 36, the efficacy of the molecule shown in I2 is weakened.
[0088] In some embodiments, when R2 is C1-C 36 When it is an alkyl group, R2 may include any one of -CH2CH2, -CH2, -(CH2CH2)2, -(CH2CH2)3, and -(CH2CH2)4 tert-butyl groups.
[0089] In some embodiments, when R2 is C1-C 36 In the case of an alkoxy group, R2 may include any one of -OCH2CH2, -CH2OCH2, -CH2OCH2CH2, -CH2CH2OCH2, and -CH2CH2OCH2CH2.
[0090] In some embodiments, when R2 is a substituted or unsubstituted aryl group, the substituted or unsubstituted aryl group may include at least one of a triphenylmethyl group and a methoxytrityl group. The structure of the triphenylmethyl group is shown below:
[0091] In some embodiments, R2 may further include any one of acetamidomethyl and trimethylacetamidomethyl.
[0092] When R2 is a group with large steric hindrance such as triphenylmethyl, methoxytrityl, tert-butyl, acetamidomethyl, or trimethylacetamidomethyl, the imidazoquinoline compound of the embodiment of the present application does not have the activity of stimulating TLR7 / 8 receptors itself, but can selectively release molecules with TLR7 / 8 receptor stimulating activity in the tumor, while achieving specific activation of the TLR7 / 8 receptors of immune cells in the tumor and reducing the effect on immune cells outside the tumor.
[0093] In some embodiments, when R2 is -S-R3, the molecular structure of the imidazoquinoline compound may contain a disulfide bond.
[0094] In the embodiment, R3 may include any one of a substituted or unsubstituted aryl group, a condensed ring aryl group, and a heteropolycyclic group.
[0095] When R3 is a substituted or unsubstituted aryl group, a condensed ring aryl group, or a heteropolycyclic group, the substituted or unsubstituted aryl group, the condensed ring aryl group, or the heteropolycyclic group represented by R3 can be the same as the substituted or unsubstituted aryl group, the condensed ring aryl group, or the heteropolycyclic group represented by R2 above.
[0096] In some embodiments, R3 can be a group represented by Formula II:
[0097] Wherein, X1 includes any one of n-propyl, n-butyl, n-butylamine, n-pentyl, and 2-methoxyethyl,
[0098] R4 includes C1-C 36 Alkyl, C1-C 36 Any of the alkoxy groups.
[0099] In some embodiments, X1 and X are the same or different groups. In a specific example, X1 is n-butyl, and R3 is a group represented by formula III:
[0100] In a specific example, when X and X1 are both n-butyl, the imidazoquinoline compound is represented by Formula I3:
[0101] In some embodiments, the C1-C 36 Alkyl, C1-C 36 Alkoxy groups can be respectively connected with C1-C 36 Alkyl, C1-C 36 The alkoxy groups are the same.
[0102] In the embodiment, R4 can be -(CH2CH2O) n-, wherein n=1-36, further, n=1-20, further, n=1-10, and further, n=1-5. Specifically, n can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 26, 30, 35, and other typical but non-limiting values. In specific examples, R4 can include any one of -CH2CH2O-, -CH2OCH2-, -CH2OCH2CH2-, -CH2CH2OCH2-, and -CH2CH2OCH2CH2-.
[0103] In the embodiment, R4 can be -(CH2) m -, wherein m = 1-36, further, m = 1-20, further, m = 1-10, further, m = 1-5, and specifically, m can be typical but non-limiting values such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 26, 30, 35.
[0104] In a specific example, R4 may include any one of -CH2CH2-, -CH2-, -(H2CH2)2-, -(CH2CH2)3-, and -(CH2CH2)4-.
[0105] For example, the imidazoquinoline compound shown in Formula I3 contains a disulfide bond, which is a GSH cleavage site sensitive linker. Therefore, the imidazoquinoline compound shown in Formula I3 can be cleaved into Formula I2 and / or Formula I3 under the action of high concentrations of GSH in tumor tissue and the cytoplasm of tumor cells. 31 The molecules shown play a role.
[0106] Due to the low level of GSH in lymphocytes and plasma, the imidazoquinoline compound represented by formula I3 in lymphocytes and plasma cannot effectively release the compounds represented by formula I2 and / or formula I 31 The molecules shown cannot fully bind to TLR7 / 8 receptors to cause a strong immune activation effect, resulting in no significant changes in the levels of cytokines such as TNF-α in plasma.
[0107] In some embodiments, based on the above embodiments of each group of X1, R1, R2, R3, R4 and X2, the imidazoquinoline compound represented by Formula I in the present application may include at least one of Formulas (1) to (4):
[0108] Regarding the imidazoquinoline compound represented by the above formula (1), it is a thiol derivative of 78A1. The molecule represented by formula (1) can directly bind to the TLR7 / 8 receptor and activate the TLR7 / 8 receptor. However, the molecular structure represented by formula (1) contains a thiol group -SH, which makes the molecule easily oxidized, and after oxidation, it can form a structure of formula (3), which greatly weakens its activity in activating the TLR7 / 8 receptor. However, after oxidation, the molecule represented by formula (1) can restore the structure of the -SH group in a reducing environment. Therefore, the TLR7 / 8 receptor stimulating activity of the molecular structure represented by formula (1) is affected by the environment due to the -SH group. Since the concentration of the reducing substance glutathione (glutathione, r-glutamyl cysteingl glycine, GSH) in the blood is low and the GSH content in the tumor is high, the molecule represented by formula (1) in the tumor tends to exist in the form of -SH reduced, so that the imidazoquinoline compound represented by formula (1) has good TLR7 / 8 receptor stimulating activity in the tumor. Based on the influence of the above factors, the compound represented by formula (1) can selectively release a compound having TLR7 / 8 receptor activating activity in the tumor.
[0109] The imidazoquinoline compound represented by formula (2) is a thioether compound of 78A1. The triphenylmethyl group and the sulfur atom formed by the trityl thiol (Tr-SH) structure are protective -SH structures that can be deprotected in a weakly acidic environment (e.g., trifluoroacetic acid, tumor microenvironment) to form the imidazoquinoline compound represented by formula (1). Furthermore, the trityl thiol structure may provide a steric hindrance effect, preventing the imidazoquinoline compound represented by formula (2) from efficiently activating TLR7 / 8 receptors in the blood.
[0110] The imidazoquinoline compound represented by the above formula (3) is a disulfide compound of 78A1, which has a disulfide bond. The disulfide bond is a GSH cleavage site sensitive linker. Therefore, the imidazoquinoline compound represented by formula (3) can be broken into the compound represented by the above formula (1) under the action of high concentrations of GSH in tumor tissue and the cytoplasm of tumor cells to exert its effect. Due to the low level of GSH in lymphocytes and plasma, the imidazoquinoline compound in lymphocytes and plasma cannot efficiently release molecules with TLR7 / 8 receptor activation activity, and cannot fully bind to the TLR7 / 8 receptor to cause a strong immune activation effect, thereby causing no significant change in the levels of cytokines such as TNF-α in plasma.
[0111] The imidazoquinoline compound represented by formula (4) is also a disulfide compound of 78A1, having a disulfide bond. The tumor environment easily causes the disulfide bonds, carbon-oxygen bonds, and amide bonds in the molecule to break, thereby releasing the 78A1 drug prototype structure and / or 78A1 derivatives. This allows the molecular structure represented by formula (4) to selectively release 78A1 or its derivatives in the tumor and specifically activate the TLR7 / 8 receptors of immune cells in the tumor.
[0112] After administration, the above-mentioned imidazoquinoline compounds selectively release compounds with TLR7 / 8 receptor agonist activity in the tumor, thereby making these imidazoquinoline compounds have good anti-tumor activity. At the same time, based on the low content of compounds with TLR7 / 8 receptor agonist activity released outside the tumor by these imidazoquinoline compounds, the immunotoxicity of these imidazoquinoline compounds is low.
[0113] In a second aspect, the present invention provides a method for preparing the above-mentioned imidazoquinoline compound. The synthesis process of the method for preparing the imidazoquinoline compound in the present invention is shown in Figure 1. The preparation method comprises the following steps:
[0114] Step S01: Providing compound A and compound B:
[0115] Step S02:
[0116] Compound A and compound B are subjected to a first condensation reaction in a first reaction system to obtain an imidazoquinoline compound represented by formula I;
[0117] Wherein, Y includes -COOH, Any of;
[0118] Z includes hydrogen, substituted or unsubstituted aryl, fused ring aryl, heteropolycyclic group, Any one of wherein R4 comprises C1-C 36 Alkyl, C1-C 36 Any of the alkoxy groups, X2 includes hydrogen, Any of .
[0119] The preparation method of the embodiment of the present application is to carry out a first condensation reaction between compound A and compound B, so that the amino group of the para-position of the benzene ring of compound A is acylated to form an amide bond, thereby preparing an imidazoquinoline compound shown in formula I. The preparation process of this preparation method has few process steps and a high reaction yield. At the same time, the obtained imidazoquinoline compound can be used as a prodrug, which can selectively release compound A or a derivative of compound A in the tumor after administration, thereby exciting the TLR7 / 8 receptor in the tumor. The release process of the imidazoquinoline compound having TLR7 / 8 receptor agonist activity is highly selective, and while having anti-tumor activity, it effectively avoids the increase in the content of cytokines and chemokines outside the tumor, effectively reducing the immune response outside the tumor.
[0120] Step S01:
[0121] In step S01, the substrate of the imidazoquinoline compound shown in formula I is reacted to provide compound A and compound B, wherein compound A is a TLR7 / 8 agonist, and the compound A molecule contains benzylamine, which undergoes a condensation reaction with compound B to form an acylation compound shown in formula I.
[0122] Wherein, X in compound A is the same as X in the imidazoquinoline compound shown in Formula I above, and R1 and R2 in compound B are the same as R1 and R2 in the imidazoquinoline compound shown in Formula I above, and are not further described here. Compound A and compound B can be purchased commercially.
[0123] Step S02:
[0124] In step S02, compound A and compound B are subjected to a first condensation reaction in a first reaction system, so that the amino group at the benzyl position of compound A undergoes an amidation reaction, for example, the benzylamine of compound A undergoes a dehydration condensation reaction with the carboxyl group of compound B, to form an imidazoquinoline compound represented by formula I, and the reaction is as follows:
[0125] In some embodiments, when Z includes any one of hydrogen, substituted or unsubstituted aryl, fused ring aryl, and heteropolycyclic groups, Z can be the same as or different from the above R2.
[0126] In some embodiments, when Y is Z is When compound B is shown as B1, the compound prepared by the preparation method of the present application is as follows:
[0127] At this time, the structural formula shown in I4 is different from the structure shown in formula I3 in that X1 and X in I3 are the same group, that is, the structure shown in I4.
[0128] In some embodiments, the reaction solvent that can control the first condensation reaction includes at least one of tetrahydrofuran, triethylamine, diisopropylethylamine, 4-dimethylaminopyridine, N,N-dimethylformamide, and dichloromethane, and compound A and compound B have good solubility in these solvents.
[0129] In some embodiments, the molar ratio of compound A to compound B can be controlled to be 1:1 to 1:10, further 1:1 to 1:5, specifically typical but non-limiting molar ratios such as 1:2, 1:3, 1:4, and 1:5.
[0130] In some embodiments, the concentration of Compound A in the reaction solution system of the first condensation reaction can be controlled to be 5-20 mg / ml. In specific examples, the concentration of Compound A can be 6 mg / ml, 7 mg / ml, 8 mg / ml, 9 mg / ml, 10 mg / ml, 11 mg / ml, 12 mg / ml, 13 mg / ml, 14 mg / ml, 15 mg / ml, 16 mg / ml, 17 mg / ml, 18 mg / ml, 19 mg / ml, and other typical but non-limiting concentrations.
[0131] In some embodiments, the reaction system for the first condensation reaction can be controlled to contain a condensation reagent. Specifically, the condensation reagent can be controlled to include at least one of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), N,N-diisopropylethylamine (DIEA), N,N'-diisopropylcarbodiimide (DIC), 1-hydroxybenzotriazole, 1-propylphosphoric anhydride, dicyclohexylcarbodiimide, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide. In further embodiments, the condensation reagent can be dissolved in a solvent such as a 50% ethyl acetate solution before being added to the first reaction system.
[0132] By controlling the molar ratio of compound A to compound B, the concentration of compound A in the reaction solution, and the condensation reagent, the occurrence of side reactions is effectively reduced, and the yield and purity of the imidazoquinoline compound represented by formula I are improved.
[0133] In some embodiments, the molar ratio of Compound A to the condensation reagent can also be controlled. Further, the molar ratio of Compound A to the condensation reagent can be controlled to be 1:3 to 1:15, and further, 1:3 to 1:10. For example, specific examples may include typical but non-limiting molar ratios such as 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, and 1:10. Controlling the molar ratio of Compound A to the condensation reagent within this range further reduces side reactions. In specific examples, the molar ratio of Compound A to Compound B can be controlled to be 1:5, and the molar ratio of Compound A to T3P can be controlled to be 1:10. At this point, no significant byproducts are observed in the reaction product, and a relatively clean target product can be obtained after extraction of the substrate.
[0134] In some embodiments, the reaction temperature of the first condensation reaction can be controlled to be 20-25° C., specifically, typical but non-limiting temperatures such as 20° C., 21° C., 22° C., 23° C., 24° C., and 25° C.
[0135] In some embodiments, the reaction time of the first condensation reaction can be controlled to be 2 to 18 hours, and specifically, the reaction time can be 2 hours, 5 hours, 10 hours, 15 hours, 18 hours, and other typical but non-limiting reaction times.
[0136] By controlling the reaction temperature and reaction time of the first condensation reaction within this range, the occurrence of side reactions can be effectively reduced, the yield of the target product can be increased, and energy consumption can be reduced while improving the preparation efficiency.
[0137] In some embodiments, when Z in compound B is hydrogen, the molecular structure of the product of the first condensation reaction is as shown in the above formula I2,
[0138] The molecular structure of Formula I2 contains a thiol group, and the two molecules of Formula I2 can also be controlled to condense by dehydrogenation and oxidation between the thiol groups. As shown in FIG2 , after the first condensation reaction, the preparation method of the embodiment of the present application can also be controlled to include:
[0139] Step S021: subjecting the product of the first condensation reaction to a second condensation reaction.
[0140] Through step S021, the sulfhydryl groups between the molecules of the first condensation reaction product represented by formula I2 are deoxidized to form disulfide bonds, and the two molecules represented by formula I2 form a dimer represented by formula I5.
[0141] The difference between the structural formula represented by Formula I5 and the structural formula represented by the above-mentioned Formula I3 is that when X1 and X in Formula I3 are the same group, and R1 and R4 are the same group, the structural formula represented by Formula I5 is obtained.
[0142] In some embodiments, after the first condensation reaction and / or the second condensation reaction, the solvent in the reaction solution may be removed, and the target product in the concentrated reaction solution may be extracted and separated using an oil-water mixture. The oil phase may be dried, and the oil phase solvent may be removed to obtain the imidazoquinoline compound represented by Formula I. In further embodiments, the oil-water mixture is a mixture of ethyl acetate and water. The imidazoquinoline compound has good solubility in ethyl acetate, which is beneficial for improving the extraction rate. Ethyl acetate is also volatile, which facilitates the subsequent removal of the oil phase solvent.
[0143] The third aspect of the embodiments of the present application provides the use of the above-mentioned imidazoquinoline compound in the preparation of anti-tumor drugs and / or antiviral drugs.
[0144] Based on the examples of the present application, the imidazoquinoline compound selectively releases molecules with TLR7 / 8 receptor agonist activity in tumors, increases the content of inflammatory mediators in tumors, and effectively avoids the increase of pro-inflammatory cytokines such as TNF-α in plasma, making the imidazoquinoline compound have great application potential in the preparation of anti-tumor drugs. In addition, due to the activation of the human immune system by the imidazoquinoline compound, the imidazoquinoline compound has a good antiviral effect, making it applicable to the preparation of antiviral drugs.
[0145] In some embodiments, when preparing an anti-tumor drug, the tumor may include a solid tumor. In further embodiments, the solid tumor may include at least one of T-cell lymphoma, melanoma, breast cancer, colorectal cancer, lung cancer, pancreatic cancer, prostate cancer, ovarian cancer, bone cancer, and brain tumor. Solid tumors are more easily administered via intratumoral injection, further increasing the accumulation of molecules with TLR7 / 8 receptor agonist activity in the tumor, thereby further enhancing the anti-tumor effect of the imidazoquinoline compounds of the present invention.
[0146] In some embodiments, the administration of the anti-tumor drug may include, but is not limited to, at least one of intratumoral injection, peritumoral injection, subcutaneous injection, and intravenous injection.
[0147] In some embodiments, when the imidazoquinoline compound of the present invention is used to prepare an anti-tumor drug, the dosage can be 0.0005-0.04 mg / kg. In exemplary embodiments, the dosage can be 0.0005 mg / kg, 0.0006 mg / kg, 0.0007 mg / kg, 0.0008 mg / kg, 0.0009 mg / kg, 0.001 mg / kg, 0.002 mg / kg, 0.003 mg / kg, 0.004 mg / kg, 0.005 mg / kg, 0.006 mg / kg, 0.007 mg / kg, 0.008 mg / kg, 0.009 mg / kg, 0.01 mg / kg, 0.02 mg / kg, 0.03 mg / kg, 0.04 mg / kg, and the like, or any dosage between any two numerical ranges. Controlling the dosage of the anti-tumor drug within this range further improves the effect of the anti-tumor drug and reduces adverse reactions.
[0148] In some embodiments, when preparing antiviral drugs, the virus may include hepatitis B virus (HBV).
[0149] In a further embodiment, when the imidazoquinoline compound is used to prepare an antiviral drug, the administration of the antiviral drug may include, but is not limited to, at least one of subcutaneous injection, intraperitoneal injection, and intravenous injection.
[0150] In a fourth aspect, an embodiment of the present application provides a composition comprising the above-mentioned imidazoquinoline compound.
[0151] After administration of the composition of the embodiment of the present application, the imidazoquinoline compound contained in the composition can act as a prodrug, selectively releasing molecules with TLR7 / 8 receptor stimulating activity in the tumor, activating immune cells in the tumor, and promoting the increase of pro-inflammatory cytokines such as TNF-α, with good selectivity.
[0152] In some embodiments, the composition of the embodiments of the present application may be a pharmaceutical composition. Furthermore, the pharmaceutical composition may also include pharmaceutically acceptable excipients.
[0153] In some embodiments, the composition can be administered by injection, further comprising at least one of subcutaneous injection, intratumoral injection, and intravenous injection, and further comprising at least one of rapid intratumoral injection, controlled intratumoral injection, rapid subcutaneous injection, controlled subcutaneous injection, and intravenous injection. Rapid intratumoral injection involves injecting the drug into the tumor tissue in a short period of time using a conventional syringe, while controlled intratumoral injection involves controlling the flow rate via an indwelling needle using a microinjection pump to maintain the drug concentration in the tumor tissue within an effective concentration range over the duration of the continuous injection.
[0154] The following are several specific examples to illustrate the imidazoquinoline compounds of the present application and their preparation methods, applications, and compositions.
[0155] 1. Examples of imidazoquinoline compounds and their preparation methods
[0156] Example A1
[0157] This embodiment provides an imidazoquinoline compound represented by formula (1), wherein the imidazoquinoline compound is 78A1-SH. The preparation process of 78A1-SH is as follows:
[0158] To a 100 mL single-necked flask, 78A1 (200 mg, 0.557 mmol), mercaptopropionic acid (295 mg, 2.78 mmol), and THF (10 mL) were added and dissolved under magnetic stirring. A 50% T3P solution in ethyl acetate (1.77 g, 5.57 mmol) was added and mixed. Triethylamine (169 mg, 1.67 mmol) was then slowly added dropwise. After mixing, the reaction mixture was stirred at room temperature for 2 hours to carry out the first condensation reaction. After the reaction, the reaction mixture was concentrated to remove the THF. Ethyl acetate and water were added and stirred to separate the liquids. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. Purification yielded 40 mg of the desired product, with a purity of 78A1-SH of 91.5%. The H NMR spectrum of 78A1-SH is shown in Figure 3.
[0159] Example A2
[0160] The imidazoquinoline compound represented by formula (2) provided in this embodiment is 78A1-S-Trity, and the preparation process is as follows:
[0161] To a 100 mL single-necked flask, 78A1 (200 mg, 0.557 mmol), 3-(tritylthio)propionic acid (967 mg, 2.78 mmol), and THF (10 mL) were added and dissolved under magnetic stirring. A 50% T3P ethyl acetate solution (1.77 g, 5.57 mmol) was added and stirred. Triethylamine (169 mg, 1.67 mmol) was then slowly added dropwise and stirred. The reaction mixture was stirred at room temperature for 2 h to carry out the first condensation reaction. After the reaction, the reaction mixture was concentrated to remove the THF. Ethyl acetate and water were added and stirred to separate the liquids. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. Purification yielded 50 mg of the desired product. The H NMR spectrum of 78A1-S-Trity is shown in Figure 4.
[0162] Example A3
[0163] This embodiment provides an imidazoquinoline compound represented by formula (3). The imidazoquinoline compound is 78A1-SS-78A1. The preparation process of 78A1-SS-78A1 is as follows:
[0164] Compound 78A1 (200 mg, 0.556 mmol) and dithiobissuccinimidyl propionate (103.60 mg, 0.278 mmol) were added to a 10 mL sealed tube equipped with a magnetic separator. 3 mL of N,N-dimethylformamide was then added and stirred to dissolve. Triethylamine (84.45 mg, 0.835 mmol) was slowly added dropwise. The mixture was stirred and allowed to react overnight at room temperature. After LCMS confirmed the completion of the reaction, the reaction solution was purified by HPLC to yield 110 mg. The H NMR spectrum of 78A1-SS-78A1 is shown in Figure 5 , and the mass spectrum is shown in Figure 6 .
[0165] 2. Activity test of imidazoquinoline compounds
[0166] Example B1: Detection of the induction expression activity of TNF-α in lymphocytes
[0167] Whole blood was extracted from SPF-grade BALB / C female mice, 5-6 weeks old, weighing 18-20 grams, by enucleation. Lymphocytes were isolated from the peripheral blood. An equal volume of whole blood diluent was added to the whole blood and mixed thoroughly. The blood was then added to an equal volume of mouse peripheral blood lymphocyte separation medium. The centrifuge was set to 1000g for 20 minutes. The lymphocyte layer was carefully removed, washed with 10 mL of phosphate-buffered saline (PBS), and centrifuged at 250g for 10 minutes. The supernatant was discarded, and the lymphocytes were resuspended in complete RPMI-1640 cell culture medium. The mouse whole blood diluent and lymphocyte separation medium used in the experiment were purchased from Beijing Solebow Technology Co., Ltd.; the mouse peripheral blood lymphocyte separation medium kit is available as catalog number P8620.
[0168] R848 (control), 78A1 (control), 78A1-SH, 78A1-S-Trityl, and 78A1-SS-78A1 were prepared at low, medium, and high concentrations in RPMI-1640 cell culture medium. 78A1-SH readily polymerizes into dimers, so some 78A1-SH exists as dimers during storage or in solution. R848 and 78A1 served as controls, while 78A1-SH, 78A1-S-Trityl, and 78A1-SS-78A1 served as experimental groups. RPMI-1640 cell culture medium served as a blank control.
[0169] Among them, the structural formula of R848 is as follows:
[0170] 100 μL of RPMI-1640 cell culture medium of each group was added to 100 μL of 1.5×10 5 Each group of peripheral lymphocyte culture solutions was prepared in each well containing normal lymphocytes, and the concentrations of different compounds in each peripheral lymphocyte culture solution were as shown in Table 1. Since 78A1-SS-78A1 is a dimer, the molar concentration of 78A1-SS-78A1 is half that of 78A1.
[0171] Table 1
[0172] The peripheral lymphocyte culture solution of each group was placed in a 37°C, 5% CO2 cell culture incubator for 24 hours, centrifuged at 1000 rpm for 5 minutes, and the cell supernatant was collected. The TNF-α concentration in the supernatant of the peripheral blood mononuclear cell culture solution was detected according to the ELISA instructions. The manufacturer of the mouse TNF-alpha double antibody sandwich ELISA detection kit used for detection is Wuhan Sanying, and the product number is KE10002.
[0173] The experimental results are shown in Figure 7. Within the dose range tested, TNF-α levels in the 78A1 group were significantly increased relative to the blank control group. However, TNF-α levels in the 78A1-SH, 78A1-S-Trityl, and 78A1-SS-78A1 groups remained unchanged. Furthermore, TNF-α levels were significantly increased in the medium and high R848 concentration groups. This indicates that compounds 78A1-SH, 78A1-S-Trityl, and 78A1-SS-78A1 lack significant activity in inducing TNF-α expression in lymphocytes. Due to the instability of 78A1-SH during cryopreservation, LC-MS analysis after one week of storage revealed that the majority of the compound was in the dimer form, with a smaller amount present as a monomer. Comparison of the results of the TNF-α induction assay revealed no significant difference in activity between the 78A1-SH and 78A1-SS-78A1 groups, with neither group exhibiting significant activity in inducing TNF-α expression in lymphocytes.
[0174] Example B2: Detection of TNF-α expression activity in mouse serum after subcutaneous injection
[0175] Take 78A1 and 78A1-SS-78A1, use phosphate buffered saline (PBS) as solvent, and prepare PBS solutions of 78A1 and 78A1-SS-78A1 of appropriate concentrations, respectively.
[0176] SPF-grade BALB / C female mice, 5-6 weeks old, weighing 18-20 grams, were purchased from the Henan Provincial Laboratory Animal Center and divided into three groups: Group A1, Group A2, and Group A3. Groups A1 and A2 each contained 12 mice, and Group A3 contained 3 mice.
[0177] The mice in group A1 were subcutaneously injected with 100 μL of the above-mentioned 78A1 solution, the mice in group A2 were subcutaneously injected with 100 μL of the above-mentioned 78A1-SS-78A1 solution, and the mice in group A3 were subcutaneously injected with 100 μL of PBS solution. The injection dosage of each group of mice was as shown in Table 2.
[0178] Table 2
[0179] Orbital blood was collected from three mice in Groups A1 and A2 at 5, 30, 60, and 240 minutes after subcutaneous injection. Orbital blood was collected from three mice in Group A3 1 hour after subcutaneous injection. Serum was centrifuged at 3800 rpm for 10 minutes to isolate TNF-α concentrations in the serum.
[0180] The experimental results are shown in FIG8 , wherein the significance analysis of the differences in the present application specification uses one-way / two-way ANOVA (ns: p>0.05, *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001).
[0181] Results showed that in mice in the A1 group, which received a rapid subcutaneous injection of 78A1, serum TNF-α levels significantly increased, reaching a peak within 1 hour of injection. Compared to mice injected with PBS, serum TNF-α levels in mice injected with 78A1 increased 10-30 times. In the A2 group, which received a rapid subcutaneous injection of 78A1-SS-78A1, serum TNF-α levels increased only slightly, by 1-3 times, within 4 hours of injection. This increase was significantly less in the A2 group than in the A1 group injected with 78A1.
[0182] Example B3: Detection of TNF-α induction activity in mouse serum 1 hour after subcutaneous injection
[0183] Compounds R848, 78A1, 78A1-S-Trityl, 78A1-SS-78A1, and 78A1-SH were prepared using PBS as solvent to prepare compound solutions of appropriate concentrations.
[0184] The same mice as in Example B2 were divided into six groups, B1 to B6, with 3 mice in each group. The mice in Groups B1 to B6 were subcutaneously injected with 100 μL of the above-mentioned solution containing the appropriate compound and PBS. The dosage for each group of mice is shown in Table 3.
[0185] Table 3
[0186] 60 minutes after subcutaneous injection, orbital blood was collected from mice in groups B1 to B6, and the blood was centrifuged at 3800 rpm for 10 minutes to separate the serum. The TNF-α concentration in the serum was detected using the same method as in Example B2.
[0187] The experimental results are shown in Figure 9. One hour after subcutaneous injection of R848 and 78A1, the TNF-α level in mouse serum increased significantly, significantly higher than the TNF-α level in the serum of mice subcutaneously injected with PBS. However, one hour after subcutaneous injection of 78A1-SH, 78A1-S-Trityl, and 78A1-SS-78A1, the TNF-α levels in the serum did not differ significantly from those in the PBS group, indicating that the safety of 78A1-SH, 78A1-S-Trityl, and 78A1-SS-78A1 was significantly improved at the tested doses.
[0188] Example B4: Detection of TNF-α expression induction activity in tumors and serum after intratumoral injection
[0189] The same mice as those in Example B2 were divided into three groups, namely group C1, group C2 and group C3. Group C1 and group C2 each contained 8 mice, and group C3 served as a blank control group with 2 mice.
[0190] CT-26 colon cancer cells purchased from ATCC were subcultured in a 37°C, 5% CO2 incubator using DMEM medium containing 10% fetal bovine serum. The specific method is to discard the culture supernatant and rinse the cells 1-2 times with PBS without calcium and magnesium ions. Add 3-5ml of digestion solution (0.25% Trypsin-0.53mM EDTA) to the culture flask, place it in a 37°C incubator for digestion for 1-2 minutes, and then observe the cell digestion under a microscope. If most of the cells become round and fall off, quickly return to the clean workbench and add 5ml of complete culture medium containing 10% serum to terminate the digestion. Gently blow the cells until they are completely detached and then aspirate them. Centrifuge at 250g for 8-10 minutes, discard the supernatant, add 1-2mL of culture medium and blow evenly. Add 5-6ml of culture medium per bottle, and divide the cell suspension into new T75 cm containing 5-6ml of culture medium at a ratio of 1:2 to 1:4. 2Cell culture flasks were used. Cells with good growth conditions in the logarithmic growth phase were selected and implanted into the left axilla of mice in groups C1 to C3 to establish mouse tumor models. On the day of inoculation, the tumor cell solution was centrifuged at 1000 rpm for 5 minutes, and the supernatant was discarded. The final cell concentration was adjusted to 5×10 5 cells / 100 μL, and injected subcutaneously in the left axilla to engraft tumors into mice.
[0191] About one week after inoculation, the tumor grew to 100 mm 3 Prepare appropriate concentrations of 78A1 and 78A1-SS-78A1 solutions, respectively, using PBS as the solvent. Use a 1 mL syringe to inject 50 μL of the PBS, 78A1, and 78A1-SS-78A1 solutions into the tumors of mice. The dosages administered to each group of mice are shown in Table 4.
[0192] Table 4
[0193] Orbital blood was collected from two mice in groups C1 and C2 5, 30, 60, and 240 minutes after intratumoral injection, respectively. Orbital blood was collected from two mice in group C3 1 hour after intratumoral injection. Serum was separated by centrifugation at 3800 rpm for 10 minutes. Tumor tissue was then dissected and weighed, and 0.1 g of tumor tissue was homogenized in 1.0 mL of PBS. TNF-α concentrations in serum and tumor homogenates were determined using the same assay as in Example B2.
[0194] The experimental results, shown in Figure 10 (A and B), demonstrate that rapid intratumoral injection of 78A1 significantly increased TNF-α levels in mouse serum and tumors. TNF-α levels in both serum and tumors reached peak values 1 hour after injection, with increases of 10-30 times. Furthermore, the trends in TNF-α levels in serum and tumors were essentially the same following rapid intratumoral injection of 78A1.
[0195] Within 4 hours of rapid intratumoral injection of 78A1-SS-78A1, serum TNF-α levels in mice increased only slightly, by 1-2 fold. This was significantly less pronounced than the 10-30 fold increase seen in the serum of mice injected with 78A1, demonstrating the significantly improved safety of 78A1-SS-78A1. Furthermore, the trends in TNF-α levels in the tumors of mice injected with 78A1 and 78A1-SS-78A1 were largely consistent, with significant increases compared to the PBS-injected C3 group. In both groups, TNF-α levels peaked in the tumors 1 hour after injection.
[0196] Example B5: Detection of TNF-α expression induction activity in tumors and serum after intratumoral injection
[0197] The same mice as in Example B4 were divided into five groups, namely, group D1 to group D5, with 3 mice in each group.
[0198] The mouse tumor model was established using the same modeling method as in Example B4.
[0199] About one week after inoculation, the tumor grew to 100 mm 3 R848, 78A1, 78A1-S-Trityl, and 78A1-SS-78A1 were prepared in PBS to prepare appropriate concentrations of each solution. 50 μL of the PBS, R848, 78A1, 78A1-S-Trityl, and 78A1-SS-78A1 solutions were injected into the tumors of mice using a 1 mL syringe. The dosages administered to each group of mice are shown in Table 5.
[0200] Table 5
[0201] 60 minutes after injection, orbital blood was collected from three mice in each group and centrifuged at 3800 rpm for 10 minutes to separate the serum. Tumor tissue was then dissected and weighed. 0.1 g of tumor tissue was added to 1.0 mL of PBS for homogenization. The TNF-α concentrations in the serum and tumor homogenate were determined using the same method as in Example B2.
[0202] The experimental results are shown in Figure 11 (A and B). The results show that rapid intratumoral injection of R848 and 78A1 significantly increased TNF-α levels in mouse serum. One hour after injection, TNF-α levels in mouse serum increased 10-30 times compared to the PBS control group. Rapid intratumoral injection of 78A1-S-Trityl and 78A1-SS-78A1 resulted in only a small 1-2-fold increase in TNF-α levels, significantly less than the 10-30-fold increase in TNF-α levels in the 78A1-injected group, and the difference was significant compared to the 78A1-injected group. Furthermore, there was no significant difference in TNF-α levels in the tumors of mice injected with 78A1 or 78A1-SS-78A1, but a significant increase compared to the PBS-injected group D5.
[0203] Example B6: Anti-tumor activity detection
[0204] The same mice as in Example B4 were divided into 7 groups, namely, group E1 to group E7, with 6 mice in each group, and the mouse tumor model was established using the same modeling method as in Example B4.
[0205] About one week after inoculation, the tumor grew to 100 mm 3R848, 78A1, 78A1-S-Trityl, 78A1-SH, and 78A1-SS-78A1 were prepared in PBS to appropriate concentrations and administered intratumorally to mice. Groups E1 through E6 received a 50 μL injection using a 1 mL syringe. Group E7 received a 500 μL injection using a microinjection pump over 25 hours. The doses of drugs and compounds administered to mice in groups E1 through E7 are shown in Table 6. 1 mol of 78A1-SS-78A1 is equivalent to 2 mol of 78A1 per R848.
[0206] Table 6
[0207] The mice in groups E1 to E7 of this example were dosed once every 3 days for a total of 2 doses. During the dosing process, the changes in the weight and tumor volume of the mice were measured every 2 days until 22 days after dosing. The tumor volume was measured by measuring the long diameter (l) and short diameter (w) of the tumor with a vernier caliper, according to the volume formula: v = 0.5 × l × w 2 The tumor volume was calculated. After 22 days of treatment, the mice were euthanized, and the tumors were dissected, photographed, and analyzed. The experimental results are shown in Figures 12 to 16.
[0208] As shown in Figure 12, compared with the PBS injection group, the body weight of mice receiving intratumoral rapid injection of 78A1 showed a significant decrease in the early stages of treatment. However, the body weight of mice receiving intratumoral rapid injection of 78A1-SS-78A1 10μg, 78A1-SS-78A1 20μg, and 78A1-SH did not change significantly compared with the PBS injection group.
[0209] As shown in Figures 13 to 16, rapid intratumoral injection of 10 μg of 78A1-SH, 78A1-S-Trityl, and 78A1-SS-78A1, as well as 20 μg of 78A1-SS-78A1, effectively inhibited tumor growth, with no significant difference compared to the results of 78A1 injection alone. Furthermore, when 78A1-SS-78A1 was administered with a microinjection pump (78A1-SS-78A1 10 μg CI), although tumors grew in two mice, four mice achieved tumor clearance as early as day 10. These results were no significant difference compared to the other groups, demonstrating the practical clinical research value of 78A1-SS-78A1 with a microinjection pump.
[0210] Example B7: 78A1-SS-78A1 immune activation test on PBMC cells of different species
[0211] PBMCs from five species, including human, mouse, rat, beagle, and cynomolgus macaque, were prepared. 78A1-SS-78A1 was serially diluted in RPMI-1640 cell culture medium according to the working concentrations shown in Table 7 to prepare nine concentrations. RPMI-1640 cell culture medium was used as a blank control group.
[0212] 40 μL of the above RPMI-1640 cell culture medium containing 78A1-SS-78A1 was added to 160 μL of 2.0×10 5 The PBMC cells of human, mouse, rat, dog, and monkey were added to the wells (all PBMC cells were purchased from Shanghai Aoneng Biotechnology Co., Ltd.), with three replicates for each concentration. The PBMC cell culture solution was prepared so that the concentration of 78A1-SS-78A1 in each PBMC cell culture solution was as shown in the final sample concentration in Table 7.
[0213] Table 7
[0214] After incubation for 24 hours at 37°C and 5% CO2 in a cell culture incubator, the PBMC culture solutions of each group were centrifuged at 1000 rpm for 5 minutes. The cell supernatants were collected and the levels of four cytokines, TNF-α, IL-6, IL-12p70, and IFN-α, in the supernatant culture fluid were assayed using ELISA, CBA, and MSD methods, respectively. The test results are shown in Figure 17 , where A is a schematic diagram of the results for TNF-α secretion levels, B is a schematic diagram of the results for IFN-α secretion levels, C is a schematic diagram of the results for IL-6 secretion levels, and D is a schematic diagram of the results for IL-12p70 secretion levels.
[0215] As shown in Figure 17A, human PBMCs treated with 78A1-SS-78A1 exhibited a dose-response relationship with increasing TNF-α secretion levels. Mouse PBMCs exhibited higher baseline TNF-α levels than humans, with TNF-α levels initially increasing and then decreasing with increasing drug concentration. Rat PBMCs exhibited significantly higher baseline TNF-α levels than those of other species, with TNF-α levels initially increasing and then decreasing with increasing drug concentration. TNF-α levels produced by monkey PBMCs increased with increasing drug concentration. TNF-α levels produced by dog PBMCs initially increased and then decreased with increasing drug concentration.
[0216] As shown in Figure 17B, IFN-α levels in human PBMCs initially increased after treatment with low concentrations of 78A1-SS-78A1, and then decreased slightly. IFN-α levels in PBMCs from other species did not change significantly after treatment with 78A1-SS-78A1.
[0217] As shown in Figure 17, C, human PBMCs treated with 78A1-SS-78A1 exhibited a dose-response relationship with increasing IL-6 secretion levels. Mouse PBMCs initially increased and then decreased with increasing drug concentration. Rat PBMCs exhibited an initial increase in IL-6 secretion upon treatment with low 78A1-SS-78A1 concentrations and then decreased with increasing 78A1-SS-78A1 concentrations. Monkey PBMCs exhibited a gradual increase in IL-6 secretion with increasing drug concentrations. Dog PBMCs showed no significant changes in IL-6 secretion after drug treatment.
[0218] As shown in Figure 17D, after treatment with 78A1-SS-78A1, human PBMCs initially increased IL-12p70 secretion levels, then slightly decreased, exhibiting a dose-response relationship. Following treatment with 78A1-SS-78A1, IL-12p70 secretion levels in mouse and rat PBMCs did not significantly change. Monkey PBMCs showed elevated IL-12p70 levels after treatment with high concentrations of 78A1-SS-78A1. Background IL-12p70 secretion by canine PBMCs was significantly higher than that in other species, but no apparent dose-response relationship was observed.
[0219] As shown in Figures 17A to 17D, the test compound 78A1-SS-78A1 stimulated the secretion of four cytokines, TNF-α, IL-6, IL-12p70, and IFN-α, in human PBMCs after treatment with PBMCs from different species. Compared to dogs, the trends in cytokine levels in PBMCs from mice, rats, and monkeys tested in this experiment were more similar to those in humans.
[0220] Example B8: Pharmacokinetic study of 78A1-SS-78A1 in rats
[0221] Take 78A1-SS-78A1 and use sterile water for injection as solvent to prepare 78A1-SS-78A1 solutions of appropriate concentrations.
[0222] Six SPF male SD rats weighing 180-200 g were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. The rats were divided into two groups, F1 and F2, with three rats in each group.
[0223] Rats in the F1 group were subcutaneously injected with the aforementioned 78A1-SS-78A1 solution at a dose of 0.2 mg / kg, while rats in the F2 group were intravenously injected with the aforementioned 78A1-SS-78A1 solution at a dose of 0.06 mg / kg. The doses administered to each group are shown in Table 8. Blood was collected from the jugular vein at 5, 15, 30, 1, 2, 4, 6, 8, and 12 hours after administration, with approximately 0.25 mL collected from each animal at each time point. Blood collection tubes were pre-chilled and immediately placed on ice. Within 0.5 hours of collection, the samples were centrifuged at 2000 g at 4°C for 5 minutes. Plasma was aspirated and placed in labeled EP tubes and frozen at -60 to -90°C within 0.5 hours. 78A1-SS-78A1 concentrations in EDTA-K2 anticoagulated rat plasma were determined using LC-MS / MS.
[0224] Table 8
[0225] Analyst software was used to integrate and analyze the chromatographic peaks and calculate the concentration of 78A1-SS-78A1 in rats. The results are shown in Figure 18. As shown in Figure 18, the plasma concentration of 78A1-SS-78A1 reached its peak 15 minutes after subcutaneous injection, essentially reaching a steady-state concentration 2 hours later, then decreased until it remained detectable 12 hours later. The steady-state concentration persisted for a long time, with a half-life of up to 20 hours. The plasma concentration of 78A1-SS-78A1 reached its peak 5 minutes after intravenous injection, then rapidly distributed, falling below the limit of quantification by 1 hour. The drug half-life was 3-4 minutes.
[0226] Example B9: In vivo pharmacodynamic study on a subcutaneous transplant model of murine B lymphoma cells A20
[0227] The same mice as in Example B4 were divided into 5 groups, namely G1 to G5, with 6 mice in each group, and the same modeling method as in Example B4 was used to establish a mouse tumor model. The A20 cell concentration was adjusted to 5×10 5 cells / 100 μL, and injected subcutaneously in the right axilla to engraft tumors into mice.
[0228] About one week after inoculation, the tumor grew to 100 mm 3 78A1 and 78A1-SS-78A1 were prepared into solutions of appropriate concentrations using PBS and administered to mice via intratumoral and peritumoral injection. Groups G1, G2, and G4 received a 50 μL rapid intratumoral injection using a 1 mL syringe; groups G3 and G5 received a 100 μL rapid peritumoral injection using a 1 mL syringe. The drug and compound dosages administered to mice in groups G1 through G5 are shown in Table 9.
[0229] Table 9
[0230] Mice in groups G1 through G5 of this example were dosed once every three days for a total of two doses. During the dosing process, changes in mouse body weight and tumor volume were measured every two days until 21 days after dosing, with tumor volume measurement performed in the same manner as in Example B6. After 21 days of treatment, the mice were euthanized, and the tumors were dissected, removed, photographed, and analyzed. The results are shown in Figure 19 , where A is a schematic diagram of tumor volume changes and B is a schematic diagram of the dissected tumor.
[0231] As shown in Figure 19, both intratumoral and peritumoral rapid injection of 78A1-SS-78A1 effectively inhibited tumor growth. There was no significant difference in tumor inhibition rate and tumor weight between the two groups. Furthermore, peritumoral injection of 50 μg of 78A1-SS-78A1 resulted in tumor clearance in all mice 14 days after the first dose, whereas only two mice receiving 50 μg of 78A1 peritumoral injection experienced tumor disappearance, demonstrating the superior therapeutic potential of 78A1-SS-78A1 in anti-tumor therapy.
[0232] Example B10: Pharmacodynamic Study of Intraperitoneal Injection of 78A1-SS-78A1 on Mouse Colon Cancer CT26 Model
[0233] The same mice as in Example B4 were divided into two groups, namely, group H1 to group H2, with 6 mice in each group. The same tumor cells prepared in the same manner as in Example B4 were intraperitoneally injected into the mice to establish a tumor model.
[0234] On day 2 after tumor cell inoculation, 78A1-SS-78A1 was prepared in PBS at an appropriate concentration and administered intraperitoneally to mice in a volume of 100 μL. The drugs and doses injected into mice in groups H1 and H2 are shown in Table 10.
[0235] Table 10
[0236] Mice in groups H1 and H2 of this example were dosed every other day for a total of six times. During the dosing process, the mice were weighed and their abdomens observed every two to three days. The survival of the mice was also monitored, and any near-death events were observed and recorded during the experiment. After 40 days, the experiment was terminated, and the surviving mice were euthanized. The tumors were dissected, removed, photographed, and analyzed. The survival rate of the mice is shown in Figure 20, and a schematic diagram of the abdominal anatomy of the mice is shown in Figure 21.
[0237] The in vivo antitumor activity of 78A1-SS-78A1 was studied using a CT26 cell peritoneal tumor model. As shown in Figure 20, mice in the untreated H1 group began to die 13 days after intraperitoneal injection of PBS, and all mice in the H1 group died within 21 days. In the H2 group treated with 78A1-SS-78A1, no mice died by the end of the experiment, and the survival rate was significantly improved, reaching 100%. The white dashed box in the mouse abdominal dissection in Figure 21 shows the tumors. As shown in Figure 21, mice in the H1 group had extensive peritoneal tumor growth, with a large number and size, resulting in a noticeable abdominal swelling. Mice in the H2 group, however, showed no noticeable abdominal swelling throughout the experiment. Six mice had small subcutaneous tumors. As shown in Figure 21, partial abdominal tumors were observed upon dissection, and the tumors were significantly smaller and less numerous than those in the H1 group. The results showed that compared with the PBS injection group, intraperitoneal injection of 78A1-SS-78A1 was significantly more effective in treating abdominal metastatic tumors.
[0238] Example B11: Pharmacodynamic Study of 78A1-SS-78A1 on Murine B Lymphoma A20 Subcutaneous Transplant Tumor Model
[0239] The same mice as in Example B4 were divided into 5 groups, namely, I1 to I5, with 6 mice in each group, and the same modeling method as in Example B4 was used to establish mouse tumor models. The A20 cell concentration was adjusted to 5×10 5 cells / 100 μL, and injected subcutaneously in the right axilla to engraft tumors into mice.
[0240] About one week after inoculation, the tumor grew to 80-100 mm 3 PBS was used as the solvent to prepare solutions of appropriate concentrations of 78A1 and 78A1-SS-78A1. The solutions were then injected intratumorally into mice in a volume of 50 μL. The drugs and doses injected into mice in groups I1 to I5 are shown in Table 11.
[0241] Table 11
[0242] Mice in Groups I1 and I5 of this example were dosed once every three days for a total of two doses. During the dosing period, changes in mouse body weight and tumor volume were measured every two to three days until 20 days after dosing. Tumor volume was measured using the same method as in Example B6. After 22 days of treatment, the mice were euthanized, and the tumors were dissected, removed, and photographed for analysis.
[0243] This study investigated the dose-response relationship of 78A1-SS-78A1's in vivo antitumor activity. As shown in Figure 22, the test compound 78A1-SS-78A1 exhibited significant antitumor effects in a murine B lymphoma A20 subcutaneous xenograft model, demonstrating a dose-response relationship. The tumor inhibition effect on A20 cells was dose-dependent, and the low-dose 78A1-SS-78A1 group exhibited superior antitumor activity compared to the 78A1 (4 μg / mouse) group. At the endpoint, the tumor inhibition rate (TGI) (%) of the high-dose 78A1-SS-78A1 group (I2) reached 97%, the medium-dose 78A1-SS-78A1 group (I3) achieved a TGI of 94%, the low-dose 78A1-SS-78A1 group (I4) achieved a TGI of 85%, and the 78A1 (4 μg / mouse) group (I5) achieved a TGI of only 54%. The results showed that the effective dose of 78A1-SS-78A1 in the A20 mouse model was less than 0.075 mg / kg. The effective dose in mice was 0.07 mg / kg. Based on the mouse weight of 20 g and the human weight of 70 kg, the equivalent dose for humans was approximately 0.0057 mg / kg, and the maximum starting dose for humans was approximately 0.0005 mg / kg.
[0244] Example B12: Toxicity study of repeated subcutaneous injection of 78A1-SS-78A1 in normal mice
[0245] The same mice as in Example B4 were divided into three groups, J1 to J3, with six mice in each group. 78A1 and 78A1-SS-78A1 were prepared in PBS at appropriate concentrations and administered subcutaneously to the mice in a volume of 100 μL. The drugs and dosages administered to mice in Groups J1 to J3 are shown in Table 12.
[0246] Table 12
[0247] In this example, mice in groups J1 to J3 were dosed once every three days for a total of two doses. During the dosing process, the mice were weighed every day or every other day. The activity of the mice was observed and recorded during the experiment. The weight changes of the mice are shown in Figure 23 until 14 days after the first dose.
[0248] As shown in Figure 23, the weight of untreated mice in group J1 increased normally throughout the experiment. Mice treated with 78A1 (group J2) experienced a significant transient decrease in weight the day after each dose, with a 12% to 13% decrease. This weight then slowly increased, but remained below that of the PBS control group. Mice treated with 78A1-SS-78A1 (group J3) experienced only a slight decrease in weight the day after the first dose, approximately 5%, after which their weight maintained a comparable growth trend with the PBS group. No mice died by the end of the experiment. These results indicate that repeated subcutaneous administration of 78A1-SS-78A1 had minimal effects on clinical manifestations, such as weight and activity, compared to the 78A1-injected group. Based on a 20g mouse weight, the maximum tolerated dose of 78A1-SS-78A1 in mice is greater than 5mg / kg. Based on a 70kg human weight, the human equivalent dose is approximately 0.4mg / kg, and the maximum tolerated dose for humans is approximately 0.04mg / kg.
[0249] The above embodiments merely illustrate several implementation methods of the present application. While the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art could make various modifications and improvements without departing from the spirit of the present invention, all of which fall within the scope of protection of the present invention. Therefore, the scope of protection of the present invention shall be determined by the appended claims.
Claims
1. An imidazoquinoline compound, characterized in that The imidazole or quinoline compound is a compound of formula I or a pharmaceutically acceptable salt thereof: The X includes any one of n-propyl, n-butyl, n-butylamine, n-pentyl, and 2-methoxyethyl; The R1 includes C1-C 36 Alkyl, C1-C 36 Any of the alkoxy groups; The R2 includes any one of hydrogen, substituted or unsubstituted aromatic group, condensed aromatic group, heteropolycyclic group, and -S-R3, wherein the R3 includes any one of substituted or unsubstituted aromatic group, condensed aromatic group, heteropolycyclic group.
2. The imidazoquinoline compound according to claim 1, wherein The X is n-butyl.
3. The imidazoquinoline compound according to claim 2, wherein The structure of the imidazoquinoline compound is shown in formula (1):
4. The imidazoquinoline compound according to claim 2, wherein The structure of the imidazoquinoline compound is shown in formula (2):
5. The imidazoquinoline compound according to any one of claims 1 or 2, characterized in that The R3 is shown in formula II: Wherein, the X1 includes any one of n-propyl, n-butyl, n-butylamine, n-pentyl, and 2-methoxyethyl, and the R4 includes C1-C 36 Alkyl, C1-C 36 Any of the alkoxy groups.
6. The imidazoquinoline compound according to claim 5, characterized in that The structure of the imidazoquinoline compound is shown in formula (3):
7. The imidazoquinoline compound according to claim 5, characterized in that The structure of the imidazoquinoline compound is shown in formula (4):
8. The method for preparing an imidazoquinoline compound according to any one of claims 1 to 7, wherein: The steps include: Compound A and Compound B are provided: The compound A and the compound B are subjected to a first condensation reaction to obtain the imidazoquinoline compound represented by formula I; Wherein, the Y includes -COOH, Any of; The Z includes hydrogen, substituted or unsubstituted aryl, condensed ring aryl, heteropolycyclic group, Any one of the above, wherein said R4 comprises C1-C 36 Alkyl, C1-C 36 Any of the alkoxy groups, wherein X2 includes hydrogen, Any of .
9. The preparation method according to claim 8, characterized in that: The reaction solvent of the first condensation reaction includes at least one of tetrahydrofuran, triethylamine, diisopropylethylamine, 4-dimethylaminopyridine, N,N-dimethylformamide and dichloromethane.
10. The preparation method according to any one of claims 8 to 9, characterized in that: The molar ratio of the compound A to the compound B is 1:1 to 1:
10.
11. The preparation method according to any one of claims 8 to 10, characterized in that: The concentration of the compound A in the reaction solution system of the first condensation reaction is 5 to 20 mg / ml.
12. The preparation method according to any one of claims 8 to 11, characterized in that: The reaction solution system of the first condensation reaction contains a condensation reagent, and the molar ratio of the compound A to the condensation reagent is 1:3 to 1:
15.
13. The preparation method according to claim 12, characterized in that: The condensation reagent includes at least one of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, N,N-diisopropylethylamine, N,N'-diisopropylcarbodiimide, 1-hydroxybenzotriazole, 1-propyl phosphoric anhydride, dicyclohexylcarbodiimide, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.
14. The preparation method according to any one of claims 8 to 13, characterized in that: The reaction temperature of the first condensation reaction is 20-25°C.
15. The preparation method according to any one of claims 8 to 14, characterized in that: The reaction time of the first condensation reaction is 2 to 18 hours.
16. The preparation method according to any one of claims 8 to 15, characterized in that: When Z is hydrogen, after the first condensation reaction, the preparation method further comprises performing a second condensation reaction between the product molecules of the first condensation reaction, wherein the second condensation reaction is a thiol dehydrogenation oxidation reaction, wherein the thiol group is the thiol group contained in the imidazoquinoline compound shown in Formula I.
17. Use of the imidazoquinoline compound according to any one of claims 1 to 7 in the preparation of antitumor drugs and / or antiviral drugs.
18. The use according to claim 17, characterized in that The tumor includes a solid tumor, and the solid tumor includes at least one of skin T-cell lymphoma, melanoma, breast cancer, colorectal cancer, lung cancer, pancreatic cancer, prostate cancer, ovarian cancer, bone cancer, and brain tumor.
19. The use according to claim 17 or 18, characterized in that The administration method of the anti-tumor drug may include at least one of intratumor injection, peritumoral injection, subcutaneous injection, and intravenous injection.
20. The use according to any one of claims 17 to 19, characterized in that: The dosage of the anti-tumor drug is 0.0005-0.04 mg / kg.
21. The use according to claim 17, characterized in that The viruses include hepatitis B virus.
22. The use according to claim 17 or 21, characterized in that The administration method of the anti-tumor drug may include at least one of subcutaneous injection and intravenous injection.
23. A composition, characterized in that The invention comprises the imidazoquinoline compound as described in any one of claims 1 to 7 or the imidazoquinoline compound prepared by the preparation method as described in any one of claims 8 to 16.
24. The composition of claim 23, wherein The composition includes pharmaceutically acceptable excipients.
Citation Information
Patent Citations
Toll-like receptor stimulant requinimod derivative and preparation and application thereof
CN113816953A
4-amino-imidazo quinoline compound and application thereof
CN114599360A
Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds
US20170029421A1
Compositions and Methods for Inducing an Immune Response
US20180311334A1
Alkyl chain modified imidazoquinoline TLR7 / 8 agonist compounds and uses thereof
US20200199124A1
